Latest total assets for CBAY: $430M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Cymabay Therapeutics (CBAY) currently reports a total assets of $430M as of December 2023. That compares with $140M in the prior-year period — up 206.4% year over year. Use the charts on this page to explore Cymabay Therapeutics's total assets history and peer comparisons.
Cymabay Therapeutics's total assets increased from $140M to $430M — a 206.4% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Cymabay Therapeutics reported $430M in total assets as of December 2023. That compares with $140M in the prior-year period — up 206.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total assets of $430M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cymabay Therapeutics, and consider following CBAY for alerts when major investors trade the stock.
Cymabay Therapeutics is classified in the Healthcare sector. On total assets, it currently shows $430M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CBAY with unrelated industries.